Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score®(RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial) | Publicación